Skip over navigation
Banner
Directory
Directory Search
Jobs
Job Search Post a Job
Patient
Patient Resources Drug Development
History
Genealogy
Toons & Teasers
Industry
 Directory
 Toons & Teasers
Quick Links
 Directory
 Job Search
 Toons & Teasers
 Advertising
 
Advertising
 

EquipNet Auction: State-of-the-Art Healthcare Testing & Diagnostics Equipment - Nov. 27-30

Tickle your funny bone with our Toons & Teasers


Washington Life Science Industry Directory

https://www.cdc.gov/flu/prevent/index.html

Banner Advertising

Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and delayed by COVID-19, to be launched in 2023 replacing WashingtonLifeScience.com. Regrettably, we are working with reduced staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved directory upon the launch of the new site. We apologize for the inconvenience.

Obenomics, Inc.


Obenomics, Inc.
10398 NE 17th St, Unit 306
Bellevue, WA 98004
 
 
Phone: (425) 223-5128
Year Established:  2009
Employees: 1
Main Contact: Yansong Gu, President
 
Company Description

Obenomics is a pharmaceutical company focused on developing effective and safe therapeutic products for treating obesity and related metabolic syndromes. Obenomics is founded on the basis of new discovery and understanding of obesity and related metabolic syndromes. With robust animal mechanism-based proof of concept and preclinical safety data, one unique feature of Obenomics’ strategy is to modulate multiple signaling pathways by targeting epigenetic modification. The other feature is to specifically target the cellular origin of obesity, ie, adipose tissue.

Obenomics’ key technologies are based on patent applications directed to a novel target, the proof of concept for its anti-obesity effect in tissue-specific gene knockout mice, and compositions of novel compounds for treating obesity and related metabolic syndromes. Obenomics’ proprietary compounds are designed to target a single epigenetic modifier peripherally, for example, in mature adipocytes,to recapitulate the anti-obesity effect in the mouse model. Obenomics is currently seeking funding and collaborations to support the effort on in silico drug design, synthesis of novel compounds, and screen and validation of lead compounds using in vitro and in vivo assays.



Main Industry Directory

 
Email thie page to a friend. Email This Page
to a Friend
Print this page. Print This
Page
© 1997 - 2023 Info.Resource, Inc. All rights reserved.
Privacy Policy . Cookie Policy . Terms of Use . About . Advertising

WashingtonLifeScience.com is owned and published by Info.Resource, Inc.